Jarrod Longcor
Chief Operating Officer bij CELLECTAR BIOSCIENCES, INC.
Vermogen: 211 501 $ op 31-03-2024
Profiel
Jarrod Longcor is currently the Chief Operating Officer at Cellectar Biosciences, Inc. He previously held positions as the Senior Director of Business Development at Middlebrook Pharmaceuticals, Inc., the Director of Business Development at MaxCyte, Inc., the Vice President of Corporate Development at Melinta Subsidiary Corp., and the Chief Business Officer at Avillion LLP.
Mr. Longcor received his undergraduate degree from Dickinson College, his graduate degree from Boston University School of Medicine, and his MBA from Erivan K.
Haub School of Business.
Bekende belangen in openbare bedrijven
| Onderneming | Datum | Aantal aandelen | Totale waarde | Waarderingsdatum |
|---|---|---|---|---|
| 08-12-2023 | 53 141 ( 0.43% ) | 211 501 $ | 31-03-2024 |
Actieve functies van Jarrod Longcor
| Bedrijven | Functie | Begin |
|---|---|---|
| CELLECTAR BIOSCIENCES, INC. | Chief Operating Officer | 23-02-2022 |
Eerdere bekende functies van Jarrod Longcor
| Bedrijven | Functie | Einde |
|---|---|---|
Avillion LLP
 Avillion LLP Pharmaceuticals: MajorHealth Technology Avillion LLP operates as a drug development company that focuses on clinical development and approval of late stage pharmaceutical products and candidates. It offers global clinical trial, and global regulatory services. The firm serves pharmaceutical and biotechnology companies. The company was founded in 2012 and is headquartered in London, the United Kingdom. | Corporate Officer/Principal | 01-07-2016 |
Melinta Subsidiary Corp.
 Melinta Subsidiary Corp. Pharmaceuticals: MajorHealth Technology Melinta Subsidiary Corp. develops and markets pharmaceutical products for the treatment of life-threatening infections. It also develops novel classes of antibiotics to treat the multi- and extremely-drug-resistant pathogens for which there are few to no options, known collectively as ESKAPE pathogens. The company was founded by John N. Abelson, Harry F. Noller, Susan Froshauer, Harry H. Penner, Jr., William L. Jorgensen, Thomas A. Steitz, and Peter Moore in October 2000 and is headquartered in New Haven, CT. | Corporate Officer/Principal | 01-09-2013 |
| MAXCYTE, INC. | Corporate Officer/Principal | - |
Middlebrook Pharmaceuticals, Inc.
 Middlebrook Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology MiddleBrook Pharmaceuticals, Inc. develops and commercializes anti-infective drug products. It operates mainly in prescription pharmaceuticals. MiddleBrook's main product is PULSYS. PULSYS technology offers the prolonged release and absorption of a drug. The company was incorporated in December 1999 and is headquartered in Westlake, TX. | Corporate Officer/Principal | - |
Opleiding van Jarrod Longcor
| Dickinson College | Undergraduate Degree |
| Erivan K. Haub School of Business | Masters Business Admin |
| Boston University School of Medicine | Graduate Degree |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
| Beursgenoteerde bedrijven | 1 |
|---|---|
| MAXCYTE, INC. | Health Technology |
| Bedrijven in privébezit | 4 |
|---|---|
Middlebrook Pharmaceuticals, Inc.
Middlebrook Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology MiddleBrook Pharmaceuticals, Inc. develops and commercializes anti-infective drug products. It operates mainly in prescription pharmaceuticals. MiddleBrook's main product is PULSYS. PULSYS technology offers the prolonged release and absorption of a drug. The company was incorporated in December 1999 and is headquartered in Westlake, TX. | Health Technology |
Melinta Subsidiary Corp.
Melinta Subsidiary Corp. Pharmaceuticals: MajorHealth Technology Melinta Subsidiary Corp. develops and markets pharmaceutical products for the treatment of life-threatening infections. It also develops novel classes of antibiotics to treat the multi- and extremely-drug-resistant pathogens for which there are few to no options, known collectively as ESKAPE pathogens. The company was founded by John N. Abelson, Harry F. Noller, Susan Froshauer, Harry H. Penner, Jr., William L. Jorgensen, Thomas A. Steitz, and Peter Moore in October 2000 and is headquartered in New Haven, CT. | Health Technology |
Avillion LLP
Avillion LLP Pharmaceuticals: MajorHealth Technology Avillion LLP operates as a drug development company that focuses on clinical development and approval of late stage pharmaceutical products and candidates. It offers global clinical trial, and global regulatory services. The firm serves pharmaceutical and biotechnology companies. The company was founded in 2012 and is headquartered in London, the United Kingdom. | Health Technology |
| Cellectar Biosciences, Inc. |
